Article
AstraZeneca stock dives 9% after heart drug trial misses target
Pessimistic
-38.8
−100 Bearish
0
+100 Bullish
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Sentiment Signal
Pessimistic
-38.8
−100Neutral+100
More Like This